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Interleukin 1 and tumour necrosis factor alpha may be responsible for the
lytic mechanism during anti-tumour antibody-dependent cell-mediated
cytotoxicity
A-M Pullyblank. PJ Guillou and JRT Monson
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Summan Antibodies are thought to bring about tumour cell lvsis by antibods-dependent cell-mediated
cvtotoxicitv (ADCC). but the exact mechanism is not well elucidated. Monocvtes are known to be important
mediators of anti-tumour ADCC and are also known to secrete the cvtokines tumour necrosis factor alpha
(TNF-m) and interleukin lp (IL-1p). both of which have been shown to bnrng about tumour cell lysis. We
examined the release of these cvtokines during ADCC and attempted to elucidate which components of the
ADCC reaction were necessary for cytokine production. We measured TNF-M and IL-Ip in supernatants
collected from a standard ADCC assay using each of the anti-colorectal antibodies ml7-lA. c17-1A and
cSF25. We found that there was significant TNF-m and IL-lp release during ADCC mediated by each of these
three antibodies and that the magntude of cytokine release seemed to reflect the degree of tumour cell Iysis
produced by each antibody. Furthermore. se found that effector cells. target cells and a specific anti-tumour
antibody A-ere necessarv for this to occur. The presence of only some of the components of the reaction or of
an irrelevant antibody produced little or no TNF-m or IL-1p. We conclude that TNF-r and IL-lp are released
u-hen an effector and tumour target cell are united by a specific tumour antibody and that these cytokines may
be important in bringing about tumour cell lysis during the ADCC reaction.
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Monoclonal antibodies directed against tumour-associated
antigens bring about tumour cell lysis bv antibody-dependent
cell-mediated cytotoxicity (ADCC) (Herlyn et al.. 1979).
Human peripheral blood monocytes are regarded as impor-
tant cells involved in tumour regression in viro (Fidler. 1985)
and are thought to be important mediators of ADCC (Her-
lyn et al.. 1979: McCarley et al.. 1983: Steplewski et al.. 1983.
1986: Adams et al.. 1984: Johnson et al.. 1986: Ortaldo et al..
1987: Massucci et al.. 1988: Hellstrom et al.. 1988). Activated
monocytes are known to secrete cytokines such as tumour
necrosis factor alpha (TNF-a) (Carswell et al.. 1975:
Haranaka et al.. 1984: Feinman et al.. 1987: Wilson et al..
1989) and interleukin 1p (IL-1p) (Onozaki et al.. 1985a.b;
Okusawa et al.. 1988) and both have been clearly implicated
in tumour cytotoxicity. However, very little is known about
the exact mechanisms of tumour cell lysis during ADCC. It
has been shown that targeting lymphocytes with bispecific
antibodies inhibits tumour growth by release of cytokines
resulting from receptor cross-linking (Qian et al.. 1991) and
there is one report describing a role for lymphotoxin during
ADCC (Kondo. 1981). We hypothesised. therefore. that.
since monocy-tes are important mediators of ADCC.
monocyte-derived cytokines may play a role in the lysis of
colorectal cancer cells mediated by the anti-colorectal
antibodies m17-lA. c17-lA and cSF25 during ADCC. Since
both TNF-a and IL-lp have been implicated in bringing
about tumour cell lvsis both individualls and in combination
(Ruggerio and Bagglioni. 1987: Smith et al.. 1990). the aim
of this study was to detect the presence of these monocvte-
derived cy-tokines during the ADCC assay and to establish
which if any components of the ADCC assay were necessary
for cytokine release.
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-Materials and methods
Antibodies
Three antibodies to tumour antigens were used. murine 17-
IA. chimeric 17-lA and chimeric cSF25. which are IgG2a.
IgGI and IgGl antibodies respectively. All bind to surface
antigens expressed on colorectal adenocarcinoma (Gottlinger
et al.. 1986: Sun et al., 1987; Takahashi et al.. 1988. 1989).
Irrelevant antibodies of identified isotype were also tested as
non-specific controls. For the chimeric antibodies. the control
used was a chimerised IgGl antibody. 7E3 which binds to
the platelet membrane glycoprotein Ilb Illa. RDI ID10. an
IgG2a murine antibody that reacts with cardiac myosin. was
used as a murine control. These antibodies were kindly pro-
vided by Centocor. Malvern. PA. USA. The anti-TNF-a
antibody was a rabbit IgG antibody obtained from Sigma
Immunochemicals. Poole. Dorset. UK.
Target cell cultures
The colorectal cancer cell line LS180 was a gift from Cen-
tocor. Cultures were maintained in 75 cm- tissue culture
flasks (Sterilin Laboratories. Feltham. UK) using RPMI-1640
medium (ICN Flow Laboratories. Irvine. UK) supplemented
with 10% heat-inactivated fetal calf serum (FCS) (Techgen
International. France), 100 IU ml-' penicillin and 100 mg
ml-' streptomycin at 37°C in a humidified atmosphere con-
taining 5% carbon dioxide. After 3-4 days. when the cells
had grown to confluence. they were harvested by 10 min
incubation with 10% trypsin (ICN Flow Laboratories.
Irvine. UK) and resuspension in RPMI medium with 10%
FCS. All cultures were tested to be free of mycoplasma.
Purification ofeffector cells
Peripheral blood was drawn into heparinised tubes.
Peripheral blood mononuclear cells were isolated by
Ficoll-Hypaque density centrifugation and isolation of the
interface. After three wvashes in phosphate-buffered salineTNF-z and L-10 relase dwnwg ADCC
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(PBS; ICN Flow Laboratories), the cells were resuspended in
RPMI-1640 medium supplemented with 10% FCS.
ADCC assay
Peripheral blood mononuclear cells (PBMCs) were isolated
from healthy volunteers and used in an ADCC assay using
each of the three antibodies m17-lA. c17-lA and cSF25. The
ADCC capacity of peripheral blood mononuclear cells using
each of the three anti-colorectal monoclonal antibodies had
previously been studied using an 18 h chromium-51 release
assay (Pullyblank et al., 1994). In order to measure cytokines
by enzyme-linked immunosorbent assay (ELISA), non-
radiolabelled target cells were used in the ADCC assay. A
total of 5 x 106 LS180 target cells were suspended in culture
medium at a concentration of 2 x I05cells ml-. Approx-
imately I04 cells in 50 gl of medium were placed in each well
of a 96-well plate (Nunc Intermed, Denmark) and 50pl of
effector cells was added to give effector-target cell ratios of
100:1, 50:1, 25: 1 and 12.5:1. A I0-1 aliquot ofantibody was
added to give a final concentration of 10.41g I-'. All assays
were performed in triplicate. Effector cells and target cells
without antibody were used as negative controls. Both
effector cells and targets had >95% viability as assessed by
trypan blue exclusion. The plates were incubated for 18 h at
37°C in a humidified atmosphere containing 5% carbon diox-
ide, and at the end of this period the plates were centrifuged
to pellet the cells.
Aliquots of 70 gl of supernatant were aspirated from trip-
licate wells. combined and stored at - 70°C until used in an
ELISA. All three anti-colorectal antibodies and non-specific
control antibodies were tested in parallel within the same
experiment using lymphocytes from healthy subjects. In addi-
tion. supernatants were saved from peripheral blood lym-
phocyte (PBL) preparations alone. target cells alone and cell
culture medium to ensure that any cytokine release observed
during ADCC was due to the cell lysis and not these individ-
ual cell types. A further aim of this study was to determine
which components of the ADCC reaction, target cells.
effector cells or antibody. were necessary for cytokine release.
Supernatants were therefore saved from wells containing
either PBLs and target cells alone. PBLs and antibody or
target cells and antibody. These had been prepared in parallel
with the standard ADCC assay and incubated for 18 h. Each
combination was tested using PBLs from a single subject and
each anti-colorectal antibody. m17-lA. c-17-lA and
cSF25.
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Figure 1 ELISA data shoWing levels of TNF-a in pg ml-'
detected in the supernatant of the AD-CC assay mediated by
ml7-lA. c17-lA and cSF25 compared with TNF-a release seen
when effector and target cells alone are incubated together. There
is significantly more TNF-a release in the presence of any
antibody compared with that released with effector and target
cells alone, and this seems to increase in the presence of the more
potent antibody. cSF25.
ADCC assay using anti-TNVF-L antibodies
In order to confirm a role for TNF-a during ADCC
mediated by ml7-lA. c17-lA and cSF25. the ADCC assay
was repeated in the presence of anti-TNF-a blocking
antibodies. The assay was carried out as descnrbed above
except that 5 x 106 LS180 target cells were labelled with
150 Ci of chromium-51 (Na2'CrO4. Radiochemical Centre,
Amersham, UK) in 500 ml of phosphate-buffered saline
(PBS) for 1 h at 37C. After three washes they were then
resuspended in culture medium at a concentration of
2 x 0I cells ml-' and used in the ADCC assay as described
above using PBLs from control subjects but in the presence
of an anti-TNF-a antibody at a concentration of 2jig ml-'.
Using the ELISA data, the amount of anti-TNF-a antibody
used was calculated to be ten times that needed to neutralise
the amounts of TNF-a known to be released during the
ADCC reaction. Furthermore, preliminary experiments had
shown that increasing the amount of blocking antibody
above this level of 2 jigml-' produced no further inhibition
of ADCC activity. At the end of the 18 h incubation at 37C,
70pl aliquots of supernatant were aspirated and counted in a
gamma-o counter. The spontaneous release was measured
from wells to which culture medium alone was added and the
maximum release was measured on wells to which 5% Triton
X had been added. The percentage specific lysis was cal-
culated according to the formula:
release in sample -spontaneous release
Lysis (%o)= x 100
maximum release - spontaneous release
Cytotoxicity data were analysed by area under the curve
(AUC) of four effector-target ratio points (Dye et al.. 1991).
The results are therefore expressed as AUC units ± standard
error of the mean.
C)vtokine ELISA
This was a standard 4 stage sandwich ELISA carried out in a
microtitration well which had been coated with a monoclonal
antibody specific for either TNA-x or IL-1p. The intensity of
a resultant colour change was proportional to the amount of
cytokine present in the biological sample, and this was read
with a microtitration plate reader. Each sample was run in
duplicate. Commercially availab'e ELISA kits were used to
detect both TNF-a and IL-lp (Cistron Biotechnology. NJ,
USA).
Limulus amoebocyte lvsate assay
All antibodies and reagents were tested negative for
endotoxin by a commercially available Limulus amoebocyte
lysate assay (Pyrotell, Associates of Cape Cod, MA,
USA).
Statistical analvsis
Significance within each patient group was determined using
Student's paired t-test and by Student's unpaired t-test
between groups. A probability of less than 5% (P<0.05) was
considered significant.
Results
C}vtokine release during ADCC mediatedby cSF25, ml7-lA
and c17-lA
Significant levels of TNF-a were detected during ADCC
mediated by each of the three anti-colorectal antibodies com-
pared with minimal levels in the presence of effector and
target cells alone without antibody. The results
(median ± interquartile range) are expressed as pg ml-' and
are demonstrated graphically in Figure 1. In this and all the
following graphs, the lower and upper limits of the ELISA
were 10 pg ml-' and 2000pgml-1 respectively. In order to
demonstrate this graphically. all points greater thanTNW and IL-1prlease dunng ADCC
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2000 pg ml-1 are expressed as being equal to 2000 pg ml-'
and all values <10 pg mlV-' are expressed as Opg ml -, In the
presence of effector cells and target cells without anti-tumour
antibody minimal or low levels of TNF-a were detected [O
(0-34 pg ml-')]. Significantly higher levels (P<0.02) were
detected in the presence of m17-lA [337 (0-2000pgml-')],
c17-lA [436 (157-804pgml-1)] and cSF25[825 (354-1582
pgml-')]. The amount of cytokine detected was greater in
the presence of the more potent antibodies, the increase in
TNF-a secretion corresponding to the pattern of greater
ADCC. In order to demonstrate this pattern of ADCC more
clearly, the previously published data in Figure 2 (Pullyblank
et al., 1994) show that, of the three anti-tumour antibodies.
cSF25 is the most effective mediator of ADCC, with ml7-lA
being the least potent. For IL-lp the trend was similar
(Figure 3). However, in this case there was a baseline secre-
tion of IL-lp in the presence of effectors and target cells
without antibody [1080 (382-2000 pg ml')]. This
significantly increased (P<0.002) in the presence of ml7-lA
[1512 (1149-2000pgml-')], c17-lA [1484 (1139-2000pg
ml-')] and cSF25 [2000 (1426-2000pgml-')]. Again, the
pattern of IL-lp release mirrored the amount of cytotoxicity
seen with each of the three antibodies (Figure 2). It therefore
seems that there is greater release of both TNF-a and IL-lp
in the presence of more tumour cell lysis.
C}tokine release and the components ofADCC
In order to determine which components of the ADCC reac-
tion were necessary for cytokine release, effector cells alone
were incubated with each of the three antibodies. There were
negligible or very low levels of TNF-a release in the absence
of effector cells. This was the case in the presence of either
m17-lA [O (0-0 pg ml-')]. c17-lA [59 (0-73 pg ml-)], cSF25
[7(0-47pgml-')]; or no antibody [O (-0 pgml-')] (Figure
4). The results were similar for IL-lp with very low levels of
cytokine release in the absence of antibody [26
(0-587pgrml-')] or in the presence of ml7-lA [O
(0-70pgml-')]. c17-lA [O (-0Opgml-')] or cSF25 [O
(25-1141 pgml-')] (Figure 5). For both cytokines these
results were significantly different for effectors and antibody
alone when compared with the full ADCC assay for each
antibody (P<0.05).
It seemed, therefore, that target and effector cells needed to
be united by an antibody in order to bring about cytokine
release. However, in order to test whether this antibody
needed to be specific. cytokine levels were measured in super-
natants from ADCC assays using both chimeric and murine
irrelevant antibodies. For TNF-a, there were no detectable
levels of this cytokine in an ADCC assay using the murine
antibody RDlI D0 or the chimeric control antibody 7E3.
300
Similarly. IL-lp levels were undetectable in supernatants
from assays using either the murine control or the chimeric
control (Figure 6).
Control experiments
No cytokines were detected in the presence of either of the
antibodies alone or in supernatants from PBLs or target cells
alone. Likewise, no TNF-a or IL-lp was detected when
target cells were incubated with ml7-lA. cl7-lA. cSF25 or
either of the control antibodies (Figure 7). All cell lines,
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Fgue 3 ELISA data shoWing levels of IL-P in pg ml-' detected
in the supernatant of the ADCC assay mediated by m17-1A.
c17-IA and cSF25 compared With IL-lp release seen when
effector and target cells alone are incubated together. The
presence of each of these antibodies significantly increases IL-lp
release above that seen with effector and target cells alone.
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Fgre 4 ELISA data demonstrating TNF-x release in pg ml-'
and the components of ADCC. Little or no TNF-a is released in
the absence of target cells. It is only when effector and target cells
are incubated with antibody that significant TNF-a release
occurs.
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Fiure 2 AUC units for ADCC mediated by ml7-lA. c17-lA
and cSF25 compared with lysis mediated by effector cells alone
against the cell line LS180. Results show means ± s.e.m. for 22
control patients. *Increase above no antibody (P<0.000l). tlnc-
rease above m17-lA(P=0.008). 4increase above m17-1A
(P<0.0001) and c17-lA (P=0.001).
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Fgre 5 ELISA data demonstrating IL-lp release in pg ml-'
and the components of ADCC. Little or no IL-lp is released in
the absence of target cells. It is only when effector and target cells
are incubated with antibody that significant IL-l1 release
occurs.
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Murine control MAb Chimeric control MAb
E
Fgre 6 ELISA data showing levels in pgml-' of IL-lp (-)
and TNF-a () detected in the supernatant of the ADCC assay
mediated by irrelevant murine and chimeric antibodies. There is
little or no cytokine release with the murine or chimeric irrelevant
antibody in the presence of either effector and target cells
together or effector cells alone. There are no significant
differences between anv of the groups.
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Figure 8 AUC units for ADCC mediated b; ml7-lA. c17-lA
and cSF25 in the presence and absence of 0.2gg ml-l anti-TNF
antibody against the cell line LS180. Results show means ± s.e.m.
for ADCC assays performned with PBLs from eight subjects for
m17-1A. seven subjects for c17-IA and from 12 for cSF25.
*P<0.005 vs m17-lA. tP<0.0001 vs c17-lA and 'P<0.01 vs
cSF25.
c17-lA cSF25
Fgre 7 ELISA data showing IL-1p (0) and TNF-a (0)
release in the absence of effector cells. i.e. target cells plus or
minus one of the antibodies ml7-1A, c17-lA and cSF25. There
was no cytokine release in any of these experimental situa-
tions.
culture medium and antibody preparations were tested
negative for endotoxin using the Limulus amoebocyte lysate
assay.
Inhibition ofADCC using anti-TNF-a antibodies
The results (AUC units ± s.e.m.) show that anti-TNF-a
antibody significantly abrogated ml7-lA-. ci7-lA- and
cSF25-mediated killing (Figure 8). The presence of anti-TNF-
a antibody reduced tumour cell lysis from 140 ± 34 to
62 ± 19 for m17-lA, from 257 ± 26 to 209 ± 28 for c17-lA
and from 309 ± 18 to 282 ± 21 for cSF25 (P<0.004). Sur-
prisingly. blocking TNF-a activity produced a mean reduc-
tion in cytotoxicity of 55% ± 9% with ml7-lA but of only
20% ± 3% with c17-lA and 10% ± 3% with cSF25 despite
maximal doses of blocking antibody. This appear to be in
contrast to the results of the ELISA, which suggest that more
TNF-x is present during ADCC mediated by the chimeric
antibodies.
Discussion
TNF-a and IL-l0 are known to be released by activated
monocytes and are cytotoxic to tumour cells. We have dem-
onstrated that both these cytokines are released during
ADCC mediated by the three anti-colorectal antibodies ml7-
IA, c17-lA and cSF25. This cytokine release only appears to
occur when an effector and target cell are united by a target-
specific monoclonal antibody since little or no TNF-a or
IL-lp was detected in the absence of antibody or in the
presence of an irrelevant antibody. We have previously
examined these anti-colorectal cancer antibodies for their
ability to mediate ADCC (Pullyblank et al.. 1994). We com-
pared the chimeric antibody. cSF25. which appears to be
more tumour specific (Takahashi et al., 1988. 1989) with
murine 17-lA (mI7-lA) and chimeric 17-lA (c17-lA), which
bind to the 17-lA antigen expressed on both normal colonic
mucosa and gastrointestinal adenocarcinomas (Gottlinger et
al.. 1986; Sun et al.. 1987). We found that cSF25 was the
most efficient mediator of ADCC and that both the chimenrc
antibodies were more effective anti-tumour agents than the
murine antibody ml7-lA. The data presented here seem to
suggest that more cytokines are released in the presence of
antibodies which are more efficient mediators of tumour cell
lysis.
This was more apparent for IL-lp release. but the data for
TNF-a release showed a similar trend, with a stepwise inc-
rease in cytokine release from m17-lA to c17-4A and cSF25
respectively. Since the level of tumour cell lysis seems to
parallel that of cytokine release it seems logical to suggest
that IL-li and TNF-a may play a role in mediating cytotox-
icity during ADCC. In addition, we have previously
examined monocyte activation markers in the presence of
each of these three antibodies. We found an increase in the
expression of the monocyte activation markers, IL-2r and
HLA-DR. on monocytes present in the ADCC assay, and
this increase was greater in the presence of the antibodies
which produced the most tumour cell lysis, again increasing
in a stepwise fashion from m17-lA to c17-lA and cSF25.
Monocytes have previously been demonstrated to be impor-
tant mediators of ADCC (Herlyn et al.. 1979; McCarley et
al., 1983; Steplewski et al., 1983. 1986; Adams et al., 1984;
Johnson et al., 1986; Ortaldo et al.. 1987; Hellstrom et al.,
1988; Massucci et al.. 1988) and we concluded that this
activation data supported this. Considering that TNF-a and
IL-lp are mainly monocyte derived cytokines. it seems that
activated monocytes are the most likely cell group releasing
these cytokines during ADCC.
Although we have specifically examined activation markers
present on monocytes and measured monocyte-denrved
cytokines, the effector cell population studied was not a pure
monocyte preparation. There may therefore be an additional
antibody effect on other cell populations which may also be
contributing to cytokine release. Although a mixed popula-
tion of effector cells is more analogous to the in 'ivo state,
future studies on the mechanism of this antibody-stimulated
killing need to be performed on pure preparations of each
individual cell group.
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It has been demonstrated that contact with tumour cells is
enough to produce monokine release (Jamncke and Mannel,
1990). so the presence of specific monoclonal antibodies may
merely facilitate this. Close proximity of effector and target
cell does seem to be important for cytokine release since,
from our data, this seems to be the only situation in which
TNF-a and IL-lp were detected. It is impossible to deduce
from our results whether linkage via our particular anti-
colorectal antibodies is important or whether the antibodies
purely provide a link allowing close apposition of the cells.
Webb et al. (1990) have demonstrated that engagement of the
monocyte glycoproteins LFA-3. CD-44 and CD-45 is a trig-
ger of TNF-a and IL-lp release. Again this supports the need
for a receptor-ligand interaction that mediates cell-cell
adhesion to transmit the necessary signals for release of
cytokines. However, these authors found that a further five
adhesion-activation receptors tested did not produce
monokine release, so it seems as though specific adhesion
receptors need to be engaged. It may be that linking cells
with our specific anti-colorectal cancer antibodies allowed
engagement of the necessary adhesion receptors. thus
facilitating monokine release.
Addition of purified cytokines to the cell culture at the
concentrations detected in the ELISA experiments did not
lead to tumour cell death. This has previously been described
and does not exclude these cytokines as a cause of cell death.
Firstly. TNF-a and IL-1 may not be having a direct effect
on the target cell but may only be one step in a cascade
leading to cell death that needs the presence of other soluble
and cellular factors to be effective. Secondly. we have demon-
strated the need for cell-cell contact for cytokine release.
The close apposition of effector and target cells creates a
'protected microenvironment' in which the concentration of
both TNF-a and IL-lp is presumably much higher than in
the supernatant. Locally high concentrations of cytokine are
presumably needed to bring about tumour cell death. Finally
membrane-bound TNF has been demonstrated to be impor-
tant in tumour cell lysis (Bakouche et al.. 1988: Kriegler et
al.. 1988: Luettig et al.. 1989). It is therefore possible that the
free cytokine in the supernatant is not the lethal molecule.
The levels we have measured may merely be a reflection of
the total amount of monokine present. both bound and free.
This helps to explain the conflicting results obtained when
ADCC experiments were carried out in the presence of
blocking antibodies since the free anti-TNF-z antibody is less
able to neutralise membrane-bound TNF-( activity. The
results show that TNF-a seems to play a more important role
in ADCC mediated by m17-lA than by c17-lA or cSF25, in
conflict with the ELISA data, which demonstrate more TNF
to be present when ADCC is mediated by c17-lA and cSF25.
The blocking antibodies may interfere more easily with a
system with lower levels of TNF-a than in the situation with
cl7-lA and cSF25, where the evidence suggests that there is
more TNF-x present. However, this is probably oversimplify-
ing the system. Other cytokines are undoubtedly present.
other mechanisms of cell lysis are probably in operation and
monokines such as TNF-a and IL-lp are known to act
synergistically, none of which will be demonstrated by a
simple blocking experiment. This type of experiment has
inherent problems with the amount of blocking antibody that
would need to be used to block the effect of cytokines fully.
Firstly, it is possible that the Fc end of the blocking MAb
itself will activate monocytes and. secondly, once increasing
amounts of antibody are present in the supernatant, the
ADCC reaction can be inhibited by steric hindrance from
both blocking and lytic antibodies.
The exact mechanism of ADCC is poorly understood and
its utility as a therapeutic option is thus hampered by a
limited understanding of the precise mechanism of action and
optimal conditions for administration. Reactive metabolites
of oxygen (Nathan et al.. 1980; Johnson et al.. 1986) and the
divalent cations Mg" and Ca'+ (Graziano et al.. 1989) have
been implicated as being needed for cell lysis. We have
demonstrated that when an effector and target cell are united
by a specific anti-target cell monoclonal antibody. there is a
release of TNF-a and IL-1p. which are both known to be
toxic to tumour cells. We therefore suggest that part of the
mechanism of tumour cell lysis during ADCC is due to
release of monocyte-derived cytokines. Antibodies which
cause increased release of these monokines in vitro may thus
be more effective anti-tumour agents for clinical use. It is
also possible. therefore. that the action of anti-tumour
antibodies in vivo may be augmented by selected
cvtokines.
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